STOCK TITAN

Evofem Biosciences Q3 sales fall to $4.63M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Evofem Biosciences, Inc. (EVFM) reported net sales of $4.628 million for the third quarter ended September 30, 2026, compared with $4.952 million a year earlier. Lower PHEXX ex-factory sales drove the decline; the company also cited wholesalers selling inventory purchased before the January 2026 price increase, no marketing funding, and fewer filled sales territories. Higher SOLOSEC unit sales, the January 1, 2026 wholesale average cost increase and improved gross-to-net realization partly offset those factors. Operating expenses were $3.888 million versus $4.001 million, and operating income was $740,000 versus $951,000. Net income attributable to common stockholders was $865,000, compared with a $1.680 million loss.

For the nine months ended September 30, 2026, net sales were $8.160 million versus $10.622 million, and net loss attributable to common stockholders was $15.764 million versus $2.512 million. Evofem contracted with a second pharmaceutical manufacturer to produce PHEXX and shipped its 500,000th box in July. It also added a fifth site to an ongoing NIH-funded Phase 4 SOLOSEC study.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 4 points

How the balance works

Positive

  • Minor pointQ3 common-stockholder income was $865,000, versus a $1.680 million loss.

Negative

  • Major pointNine-month common-stockholder loss rose to $15.764 million from $2.512 million.
  • Moderate pointQ3 operating income fell to $740,000 from $951,000.
  • Moderate pointNine-month net sales were $8.160 million, versus $10.622 million.
  • Minor pointQ3 net sales were $4.628 million, down from $4.952 million.

Filing Explained

As of September 30, 2026, Evofem listed no cash and cash equivalents, $317 thousand in restricted cash, and $84,776 thousand in current liabilities on its balance sheet.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter net sales $4.628 million Three months ended September 30, 2026; $4.952 million for the same period in 2025.
Third-quarter operating income $740,000 Three months ended September 30, 2026; $951,000 for the same period in 2025.
Third-quarter net income attributable to common stockholders $865,000 Three months ended September 30, 2026; a $1.680 million loss for the same period in 2025.
Nine-month net sales $8.160 million Nine months ended September 30, 2026; $10.622 million for the same period in 2025.
Nine-month net loss attributable to common stockholders $15.764 million Nine months ended September 30, 2026; $2.512 million for the same period in 2025.
Third-quarter operating expenses $3.888 million Three months ended September 30, 2026; $4.001 million for the same period in 2025.
Cash and cash equivalents $0 As of September 30, 2026.
Restricted cash and cash equivalents $317,000 As of September 30, 2026; $578,000 as of December 31, 2025.
ex-factory sales financial
"lower ex-factory sales for PHEXX"
wholesale average cost (WAC) financial
"the wholesale average cost (WAC) increase"
gross-to-net realization financial
"improved gross-to-net realization for both products"
Phase 4 clinical trial medical
"ongoing investigator-led, NIH-funded Phase 4 clinical trial"
Phase 4 clinical trials are studies done after a drug or medical product is approved and sold, designed to track long-term safety, rare side effects, and real-world effectiveness in broader patient groups. For investors, these trials matter because they can reveal new risks that hurt sales or trigger label changes or recalls, or they can uncover new uses that boost revenue—think of it like testing a car on everyday roads after showroom delivery to spot issues or extra strengths.
Third-quarter net sales $4.628 million Compared with $4.952 million in the same period of 2025.
Third-quarter operating expenses $3.888 million Compared with $4.001 million in the same period of 2025.
Third-quarter income from operations $740,000 Compared with $951,000 in the same period of 2025.
Third-quarter net income attributable to common stockholders $865,000 Compared with a $1.680 million loss in the same period of 2025.
Nine-month net sales $8.160 million Compared with $10.622 million in the same period of 2025.
Nine-month net loss attributable to common stockholders $15.764 million Compared with a $2.512 million loss in the same period of 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were EVFM's Q3 2026 sales and earnings?

EVFM reported net sales of $4.628 million for Q3 2026, compared with $4.952 million a year earlier. Net income attributable to common stockholders was $865,000, versus a $1.680 million loss in Q3 2025.

What does EVFM's SOLOSEC Phase 4 study compare?

The study compares SOLOSEC 2g oral granules as a single dose with metronidazole taken twice daily for seven days, evaluating effectiveness and cost-effectiveness for Trichomonas vaginalis in men and women. Evofem said a fifth site was added to the ongoing investigator-led, NIH-funded study.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001618835 0001618835 2026-11-13 2026-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 13, 2026

 

EVOFEM BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36754   20-8527075

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

7770 Regents Road, Suite 113-618

San Diego, CA 92122

(Address of Principal Executive Offices)

 

(858) 550-1900

(Registrant’s telephone number, including area code)

 

Not applicable.

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None        

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 13, 2026, Evofem Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information set forth in this item 2.02 and in Exhibit 99.1 is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

 

Forward-Looking Statements

 

This press release includes “forward-looking statements,” within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, “anticipate,” “could,” “estimate,” “expect,” “target,” “hypothesize,” “intend,” “potential,” “strategy,” “will,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on current assumptions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements include, but are not limited to, limited cash resources, the Company’s ability to continue as a going concern, dependence on new capital or business development transactions to fund operations, potential delays in regulatory approvals, changes in market demand, manufacturing and supply chain risks, risks related to the Company’s limited revenue base relative to operating expenses, and its reliance on third-party licensees and distributors for ex-U.S. commercialization, together with those that are disclosed in the Company’s SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 11, 2026, Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 filed with the SEC on November 13, 2026, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. Evofem undertakes no obligation to update or revise any forward-looking statement except as required by law, and investors are cautioned not to place undue reliance on such statements given the Company’s current liquidity position and evolving business conditions.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release dated November 13, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  EVOFEM BIOSCIENCES, INC.
     
Date: November 13, 2026 By: /s/ Ivy Zhang
    Ivy Zhang
    Chief Financial Officer

 

 

 

 

Exhibit 99.1

 

 

Evofem Reports Third Quarter 2026 Financial Results and Provides Business Update

 

SAN DIEGO, CA, November 13, 2026 — Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and nine-month periods ended September 30, 2026.

 

Saundra Pelletier, CEO of Evofem, said, “While third quarter net sales reflect the cumulative impact of operating without dedicated growth capital for brand promotion and physician outreach since late 2022, we are proud of the discipline, efficiency and tenacity demonstrated across the organization. Through rigorous expense management, we generated $0.7 million of operating income during the quarter while continuing to support patients and healthcare providers who rely on our innovative sexual health products. We remain confident in the long-term value of PHEXX and SOLOSEC and believe targeted investment in commercial activities would provide meaningful opportunities to accelerate growth.”

 

Highlights since July 1, 2026, include:

 

●Income from operations was $0.7 million for Q3 2026, compared to $1.0 million for Q3 2025.
  
●Net income attributable to common stockholders was $0.9 million, or $0.01 per basic and ($0.00) per diluted share, for Q3 2026, compared to a net loss of $1.7 million, or ($0.01) per basic and diluted share, for Q3 2025.
  
●Contracted with a second pharmaceutical manufacturer to produce PHEXX® (lactic acid, citric acid and potassium bitartrate), an important milestone in its strategy to support long-term growth, enhance manufacturing flexibility, and reduce costs.
  
●Shipped the 500,000th box of PHEXX in July 2026, representing hormone-free, on-demand contraception for six million acts of sex.
  
●A fifth study site was added in the ongoing investigator-led, NIH-funded Phase 4 clinical trial evaluating the effectiveness and cost-effectiveness of SOLOSEC® (secnidazole) 2g oral granules (single-dose, one time) versus metronidazole (twice daily for seven days) for the treatment of Trichomonas vaginalis in men and women. Study investigators hypothesize that the rate of repeat infections with T. vaginalis will be 1.75 lower in the SOLOSEC group versus the multi-dose oral metronidazole arm and that single-dose SOLOSEC will have higher initial cost but will be more cost effective compared to multi-dose metronidazole, largely due to lower breakthrough rates of infection.1
  
●Regulatory work is underway for SOLOSEC in Uganda, the first planned market in Sub-Saharan Africa under our April 2026 distribution agreement with Clovis Davis Pharmaceuticals.

 

1
 

 

Third Quarter Financial Results

 

For the three months ended September 30, 2026, net sales were $4.6 million, versus $5.0 million in the prior year period. The decrease was primarily due to lower ex-factory sales for PHEXX in the 2026 period. Wholesalers have continued to sell through inventory purchased in December 2025, ahead of the January 2026 price increase. Additional factors include the ongoing absence of funding for marketing and a reduction in filled sales territories in the current quarter. This was partially offset by an increase in SOLOSEC units sold, the wholesale average cost (WAC) increase that took effect on January 1, 2026, and improved gross-to-net realization for both products in the 2026 period.

 

Total operating expenses were $3.9 million in the third quarter of 2026, versus $4.0 million in the prior year period. The decrease was driven by cost containment measures across all aspects of the business.

 

Income from operations was $0.7 million, compared to $1.0 million in the prior year quarter.

 

Net income attributable to common stockholders was $0.9 million, or $0.01 per basic and ($0.00) per diluted share, in the current period versus a net loss attributable to common stockholders of $1.7 million, or $(0.01) per basic and diluted share, for the third quarter of 2025.

 

Liquidity

 


Restricted cash and cash equivalents was $0.3 million as of September 30, 2026, versus $0.6 million as of December 31, 2025.

 

About Evofem

 

Evofem Biosciences is a San Diego-based pharmaceutical company commercializing two FDA-approved sexual and reproductive health products:

 

●PHEXX® (lactic acid, citric acid, and potassium bitartrate) - the first and only hormone-free, on-demand prescription contraceptive vaginal gel. Visit phexx.com to learn more and for important safety information.
  
●SOLOSEC® (secnidazole) 2g oral granules - an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information.

 

PHEXX® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.

 

2
 

 

Forward-Looking Statements

 

This press release includes “forward-looking statements,” within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, “anticipate,” “could,” “estimate,” “expect,” “target,” “hypothesize,” “intend,” “potential,” “strategy,” “will,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on current assumptions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements include, but are not limited to, limited cash resources, the Company’s ability to continue as a going concern, dependence on new capital or business development transactions to fund operations, potential delays in regulatory approvals, changes in market demand, manufacturing and supply chain risks, risks related to the Company’s limited revenue base relative to operating expenses, and its reliance on third-party licensees and distributors for ex-U.S. commercialization, together with those that are disclosed in the Company’s SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 11, 2026, Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 filed with the SEC on November 13, 2026, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. Evofem undertakes no obligation to update or revise any forward-looking statement except as required by law, and investors are cautioned not to place undue reliance on such statements given the Company’s current liquidity position and evolving business conditions.

 

Sources

 

1. National Institute of Allergy & Infectious Diseases (NIAID) of the National Institutes of Health. Award number R01AI183266: Refining Trichomonas vaginalis treatment in women and men.

 

Connect with Us

 

ir@evofem.com

media@evofem.com

 

— Financial Tables Follow —

 

3
 

 

EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

 

(unaudited)
(In thousands)

 

   As of 
   September 30, 2026   December 31, 2025 
Cash and cash equivalents  $-   $- 
Restricted cash and cash equivalents  $317   $578 
Trade accounts receivable, net  $3,663   $12,480 
Total current liabilities  $84,776   $84,820 
Total stockholders’ deficit  $(83,927)  $(74,336)
Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit  $7,261   $20,274 

 

4
 

 

EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

(unaudited)
(In thousands, except share and per share data)

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2026   2025   2026   2025 
                 
Product sales, net  $4,628   $4,952   $8,160   $10,622 
                     
Operating Expenses:                    
Cost of goods sold   750    905    1,671    2,025 
Gain on change in accounting estimate on contingent royalty liability   -    (1,933)   -    (1,933)
Amortization of intangible asset   15    80    104    410 
Research and development, net   341    470    1,553    (3,819)
Selling and marketing   1,534    2,391    5,702    7,616 
General and administrative   1,248    2,088    5,448    6,296 
Total operating expenses, net   3,888    4,001    14,478    10,595 
Income (loss) from operations   740    951    (6,318)   27 
Other income (expense), net:                    
Interest income   -    3    5    13 
Other expense, net   (843)   (682)   (2,193)   (1,944)
Loss on debt extinguishment   (405)   -    (2,597)   - 
Change in fair value of financial instruments   1,512    (1,845)   (4,395)   (490)
Total other income (expense), net   264    (2,524)   (9,180)   (2,421)
Loss before income tax benefit (expense)   1,004    (1,573)   (15,498)   (2,394)
Income tax benefit (expense)   -    4    1    (3)
Net income (loss)   1,004    (1,569)   (15,497)   (2,397)
Convertible and redeemable preferred stock deemed dividends   (139)   (111)   (267)   (115)
Net income (loss) attributable to common stockholders  $865   $(1,680)  $(15,764)  $(2,512)
Net loss per share attributable to common stockholders:                    
Net income (loss) per share attributable to common stockholders:                    
Basic  $0.01   $(0.01)  $(0.12)  $(0.02)
Diluted  $(0.00)  $(0.01)  $(0.12)  $(0.02)
Weighted-average shares used to compute net income (loss) per share attributable to common shareholders:                    
Basic   137,337,773    124,385,785    135,989,122    121,037,306 
Diluted   6,814,698,261    124,385,785    135,989,122    121,037,306 

 

To access Evofem’s full financial results for the three-and nine-month periods ended September 30, 2026, as filed with the SEC on Form 10-Q on November 13, 2026, please visit https://investor.evofem.com/financial-information/sec-filings/default.aspx.

 

###

 

5

Filing Exhibits & Attachments

5 documents

Keep reading